As we continue to learn more about the link between type 2 diabetes and the increased risk of severe illness and death following a COVID-19 infection, the need to identify and address this devastating disease has never been greater.
More screening
While research continues into the relationship between COVID-19 and type 2 diabetes, the focus on higher frequency of diabetes screening and other measures to check the spread of chronic disease must be maintained. Proper management of blood glucose levels may not only lower the risk of COVID-related severe illness and death, but also slash the risk of vision problems, kidney disease and diabetes-related amputations.
The Goodbody Health Group Inc. is listed on the Canadian Securities Exchange (CSE), the Aquis Stock Exchange – Growth Market (AQSE) Apex segment, OTC, and Frankfurt Stock Exchange (FSE), providing current and prospective shareholders with multiple platforms in which to buy and sell Goodbody Health Group Inc. stock under the EPIC codes: CSE: GDBY / AQSE: GDBY / FRA: 484 / OTC: GDBYF).